Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

LAE102 IV

Phase 1Small molecule

LLaekna Limited

LAE102 IV is one of 38 small molecule programs targeting Overweight. It is currently in Phase 1.

2

Indications

3

Total Trials

2

Active Trials

37

Competitors

Pipeline

Status by Indication[3][1]

Indication

OverweightRecruiting

Overweight and ObesityRecruiting

OverweightPhase 1

Recruiting

Overweight and ObesityPhase 1

Recruiting

Competition

Competitive Landscape

46 competitors in Overweight

#DrugCompanyPhaseTrials

Ozempic

Mounjaro

Glucophage

Taltz

GZR18

GGan & Lee Pharmaceuticals.

IBI362

Innovent Biologics (Suzhou) Co. Ltd.

Retatrutide

HDM1002

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

RAY1225

GGuangdong Raynovent Biotech Co., Ltd

HDM1005 1

HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Recruiting

Overweight and Obesity

NCT07230496

Clinical

Trials by Indication[1]

Overweight1 trial

Evaluate LAE102 in Healthy and Overweight/Obese Subjects

Recruiting·LLaekna Limited·Phase 1·NCT06493084·160 enrolled

Postmenopausal Women1 trial

A Study to Investigate Safety, Tolerability and Pharmacokinetics of LAE102 in Postmenopausal Women

Completed·LLaekna Limited·Phase 1·NCT06908707·32 enrolled

Overweight and Obesity1 trial

A Phase I, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LAE103 as Single and Multiple Ascending Doses in Healthy Overweight/Obese Participants, and as Single Dose in Healthy Postmenopausal Women, With an Additional Evaluation of Single Ascending Dose of LAE103 in Combination With LAE102 in Healthy Overweight/Obese Participants

Recruiting·LLaekna Limited·Phase 1·NCT07230496·104 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for LAE102 IV. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LAE102 IV compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LAE102 IV. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Laekna Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: LLaekna Limited

Related News